By Rupert Hargreaves Consumer healthcare group Haleon said today that it would buy £315m of shares from Pfizer as part of the latter’s plan to reduce its stake. Haleon was created through the merger of Glaxosmithkline and Pfizer consumer healthcare arms in 2019. The two parent companies remained major shareholders after the group’s spinoff and public offering, which took place two years later in July 2022. However, Pfizer has committed to sell down its stake in a “slow and methodical” manner over time. It currently holds a 32 per cent stake in Haleon, but has said today it will reduce the posi…